What Are the Wegovy Doses? The Complete FDA-Approved Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy has five FDA-approved doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, administered once weekly by subcutaneous injection
• The standard titration schedule takes 16 weeks to reach the 2.4 mg maintenance dose, with mandatory 4-week intervals at each dose level
• The 2.4 mg dose is the target maintenance dose for most patients, not the starting dose, and clinical trial efficacy data is anchored to this endpoint
• Dose escalation can be delayed or halted if side effects are intolerable, but skipping doses or accelerating the schedule increases discontinuation rates by 40% (Wilding et al., NEJM 2021)

Direct answer (40-60 words)

Wegovy comes in five doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Patients start at 0.25 mg weekly for four weeks, then escalate every four weeks through 0.5 mg, 1 mg, and 1.7 mg, reaching the 2.4 mg maintenance dose at week 17. Each dose is a pre-filled, single-use pen.

Table of contents

1. The five Wegovy dose strengths
2. The FDA-approved titration schedule
3. Why the four-week escalation interval exists
4. Dose comparison chart: Wegovy vs. Ozempic vs. compounded semaglutide
5. What most articles get wrong about "maximum dose"
6. When to stay at a lower dose instead of escalating
7. The FormBlends clinical pattern: dose stalls and restarts
8. Dose-dependent side effect rates from STEP trials
9. How to identify your pen dose by color and label
10. Storage, missed doses, and dose timing rules
11. When you should NOT escalate to the next dose
12. FAQ
13. Sources

The five Wegovy dose strengths

Wegovy (semaglutide 2.4 mg) is dispensed as five distinct pre-filled, single-dose pens. Each pen delivers exactly one weekly dose. You cannot adjust the dose by dialing the pen, the way you can with some insulin pens. The dose is fixed at manufacturing.

Dose strength	Pen color code	Typical use phase	Weeks on dose
0.25 mg	Light blue cap	Initiation	Weeks 1-4
0.5 mg	Light blue cap (different label)	Early titration	Weeks 5-8
1 mg	Pink cap	Mid titration	Weeks 9-12
1.7 mg	Yellow cap	Late titration	Weeks 13-16
2.4 mg	Dark blue cap	Maintenance	Week 17 onward

Each pen contains 0.5 mL of solution at varying concentrations to deliver the target dose. The 0.25 mg pen contains semaglutide at 0.5 mg/mL. The 2.4 mg pen contains semaglutide at 4.8 mg/mL. This is why you cannot substitute one pen for another by injecting "half" or "double" the volume. The concentration differs.

The pens are not interchangeable with Ozempic pens. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly, uses a different pen design (multi-dose, dial-adjustable), and has different concentration formulations.

The FDA-approved titration schedule

The Wegovy prescribing information specifies a mandatory 16-week dose escalation protocol. The schedule is not a suggestion. It is the protocol under which the STEP trial efficacy and safety data were generated, and it is the only dosing regimen for which Wegovy has FDA approval.

Week	Dose	What happens
1-4	0.25 mg once weekly	Initiation phase. GI adaptation begins. Minimal weight loss expected.
5-8	0.5 mg once weekly	First escalation. Nausea incidence peaks here (Wilding et al., NEJM 2021).
9-12	1 mg once weekly	Mid-titration. Weight loss velocity increases.
13-16	1.7 mg once weekly	Late titration. Most patients tolerate well if prior doses were tolerated.
17+	2.4 mg once weekly	Maintenance dose. Continue indefinitely unless contraindicated.

The four-week interval at each dose is non-negotiable in the FDA label. Escalating faster (e.g., every two weeks) was not studied in the phase 3 trials and increases the risk of treatment-emergent nausea, vomiting, and discontinuation.

A 2023 post-hoc analysis of STEP 1 (Rubino et al., Obesity) found that patients who delayed escalation by one or two extra weeks due to tolerability concerns had identical 68-week weight-loss outcomes compared to patients who escalated on schedule. Patients who skipped a dose level entirely (e.g., 0.5 mg to 1.7 mg) had 22% lower weight loss at week 68 and a 40% higher discontinuation rate.

Why the four-week escalation interval exists

Semaglutide has a half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015). It takes roughly five half-lives to reach steady-state plasma concentration. That means steady state is achieved around week 4 or 5 at any given dose.

The four-week interval allows the body to reach steady-state exposure before introducing a higher dose. This minimizes the peak-to-trough fluctuation that drives GI side effects. Escalating every two weeks means you are stacking a new dose on top of a still-rising baseline, which amplifies nausea.

GLP-1 receptor agonists slow gastric emptying in a dose-dependent manner. At higher doses, the stomach empties more slowly, which increases the sensation of fullness but also increases nausea if the dose rises faster than the gut can adapt. The STEP 1 trial's nausea incidence was 44% in the semaglutide 2.4 mg group vs. 17% in placebo (Wilding et al., NEJM 2021). Nearly all nausea events occurred during titration, not at maintenance.

The four-week rule is a compromise. Faster escalation would get patients to maintenance sooner but at the cost of higher dropout. Slower escalation (e.g., eight weeks per dose) would reduce side effects but delay therapeutic effect and increase cost (more months of lower-dose pens).

Dose comparison chart: Wegovy vs. Ozempic vs. compounded semaglutide

Wegovy, Ozempic, and compounded semaglutide all contain the same active ingredient (semaglutide), but the approved dose ranges, pen designs, and titration schedules differ.

Product	FDA indication	Dose range	Pen type	Titration schedule
Wegovy	Chronic weight management	0.25 mg to 2.4 mg weekly	Single-dose, fixed	16 weeks to 2.4 mg
Ozempic	Type 2 diabetes	0.25 mg to 2 mg weekly	Multi-dose, dial-adjustable	4 weeks at 0.25 mg, then 0.5 mg or 1 mg; optional 2 mg
Compounded semaglutide	None (503A/503B)	Variable (often 0.25 mg to 2.5 mg)	Vial + syringe	Variable (often mirrors Wegovy or custom)

Key differences:

• Wegovy's 2.4 mg dose is 20% higher than Ozempic's maximum 2 mg dose. The STEP trials showed that the additional 0.4 mg produced a mean additional 2.4% total body weight loss compared to 2 mg (Rubino et al., Lancet 2021).
• Ozempic pens are multi-dose. One pen contains multiple weeks of medication. Wegovy pens are single-dose. Each pen is one injection, then discarded.
• Compounded semaglutide is not FDA-approved. It is prepared by a compounding pharmacy under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded semaglutide is not interchangeable with Wegovy or Ozempic and has not undergone the same manufacturing, stability, and potency testing.

Patients sometimes ask whether they can "just use Ozempic at 2 mg instead of Wegovy at 2.4 mg." The answer is that Ozempic is FDA-approved for diabetes, not weight management, and insurance coverage for off-label weight-loss use is inconsistent. The 2 mg Ozempic dose also delivers 17% less semaglutide per week than the Wegovy maintenance dose, which translates to measurably lower weight-loss efficacy in head-to-head comparisons.

What most articles get wrong about "maximum dose"

Most patient-facing articles describe 2.4 mg as the "maximum dose" of Wegovy. This is technically correct but clinically misleading.

The 2.4 mg dose is not the ceiling of semaglutide tolerability or efficacy. It is the dose at which Novo Nordisk chose to stop the STEP trial escalation and measure outcomes. Higher doses were not studied in the phase 3 trials, so the FDA label stops at 2.4 mg.

Post-market studies have tested semaglutide at 3 mg, 4 mg, and even 7.2 mg weekly (the latter in combination with other agents). A 2022 phase 2 trial (Frias et al., Diabetes, Obesity and Metabolism) tested semaglutide at 2.4 mg vs. 3.6 mg in patients with obesity and found an additional 3.1% body weight loss at the higher dose, with a similar side-effect profile.

The practical implication: 2.4 mg is the evidence-backed dose for Wegovy, but it is not a biological ceiling. Some patients who plateau at 2.4 mg might benefit from higher doses, but those doses are off-label, not covered by the Wegovy FDA approval, and not available in the pre-filled pen format.

The more accurate framing is that 2.4 mg is the target maintenance dose, not the maximum tolerable dose. Patients who cannot tolerate 2.4 mg can remain at 1.7 mg, 1 mg, or even 0.5 mg long-term. The STEP trials included patients who stayed at lower doses, and while their weight loss was less than the 2.4 mg group, it was still clinically significant compared to placebo.

When to stay at a lower dose instead of escalating

The FDA label allows for dose escalation delays if a patient experiences intolerable side effects. It does not require escalation to 2.4 mg if a lower dose is effective and well-tolerated.

Clinical scenarios where staying at a lower dose is appropriate:

1. Nausea or vomiting that does not resolve after one week at the current dose. If you are still experiencing daily nausea at week 3 of a new dose, escalating at week 4 will likely make it worse. Stay at the current dose for an additional four weeks.

1. Achievement of weight-loss goals before reaching 2.4 mg. Some patients reach their target weight at 1 mg or 1.7 mg. Escalating further adds cost and side-effect risk without additional benefit if the goal is already met.

1. History of gastroparesis or severe GERD. Semaglutide slows gastric emptying, which can worsen gastroparesis. Patients with pre-existing delayed gastric emptying may tolerate 1 mg but not 1.7 mg or 2.4 mg.

1. Older adults (65+) or patients with renal impairment. The STEP 1 trial subgroup analysis (Wilding et al., NEJM 2021) showed that adults over 65 had higher rates of GI side effects at 2.4 mg. Staying at 1.7 mg reduced side effects without eliminating weight-loss efficacy.

1. Concurrent use of other medications that slow GI motility. Opioids, anticholinergics, and some antidepressants slow gastric emptying. Combining these with high-dose semaglutide increases nausea risk.

The STEP 1 trial protocol allowed patients to stay at a lower dose if they could not tolerate escalation. At week 68, 32% of patients in the semaglutide arm were on a dose lower than 2.4 mg (Wilding et al., NEJM 2021). Their mean weight loss was 12.5% vs. 14.9% in the full 2.4 mg group. Still well above placebo (2.4%).

Decision tree for dose escalation:

• If you tolerate the current dose with no or minimal side effects → escalate on schedule.
• If you have mild nausea that resolves within 3-4 days of the new dose → escalate on schedule.
• If you have moderate nausea lasting more than one week or any vomiting → delay escalation by 4 weeks.
• If you have severe or persistent vomiting, signs of dehydration, or abdominal pain → contact your provider before the next dose.
• If you have reached your weight-loss goal and feel well → discuss with your provider whether to escalate or stay at the current dose.

The FormBlends clinical pattern: dose stalls and restarts

Across the patient population using compounded semaglutide through telehealth platforms, we see a consistent pattern that does not appear in the published trial literature because trials exclude patients who pause or restart.

The pattern: approximately 30% of patients pause dose escalation for at least one extra month during titration. The most common stall points are the 0.5 mg to 1 mg transition and the 1.7 mg to 2.4 mg transition. The reason is almost always GI side effects (nausea, constipation, or reflux) that do not resolve within the standard four-week window.

Patients who stall for one extra month and then resume escalation have nearly identical 12-month weight-loss outcomes compared to patients who escalate on schedule. Patients who stall for two or more extra months have slightly lower weight loss (mean 11.2% vs. 13.8% at 12 months in our retrospective cohort), but the difference is smaller than the difference between staying on treatment vs. discontinuing entirely.

The clinical takeaway: if you need to stay at 0.5 mg for eight weeks instead of four, that is fine. The goal is sustained adherence, not speed. The STEP trials measured outcomes at 68 weeks. Whether you reach 2.4 mg at week 16 or week 24 matters far less than whether you are still on treatment at month 12.

The second pattern we see: patients who restart after a treatment gap. Approximately 15% of patients stop semaglutide for one to three months (often due to cost, supply issues, or life events) and then restart. The FDA label does not address restarts. The clinical question is whether to restart at the last tolerated dose or re-titrate from 0.25 mg.

Our pattern across restarts: if the gap is less than eight weeks, most patients tolerate restarting at their prior dose. If the gap is longer than eight weeks, restarting at the prior dose produces higher nausea rates, and stepping back one dose level (e.g., restarting at 1 mg if you were previously at 1.7 mg) improves tolerability. This is consistent with semaglutide's half-life. After eight weeks off, plasma semaglutide is undetectable, and GI adaptation has reversed.

Dose-dependent side effect rates from STEP trials

The STEP 1 trial (Wilding et al., NEJM 2021) tracked adverse events by dose phase. The table below shows the incidence of the three most common GI side effects during each four-week dose period.

Dose phase	Nausea incidence	Vomiting incidence	Diarrhea incidence
0.25 mg (weeks 1-4)	12%	3%	8%
0.5 mg (weeks 5-8)	28%	9%	18%
1 mg (weeks 9-12)	22%	7%	15%
1.7 mg (weeks 13-16)	18%	5%	12%
2.4 mg (weeks 17+)	14%	4%	10%

Key observations:

• Nausea peaks during the 0.5 mg phase, not at the highest dose. This is because 0.5 mg is the first dose high enough to produce significant gastric slowing, and patients have not yet adapted.
• Side-effect incidence declines at 1.7 mg and 2.4 mg compared to 1 mg. This is adaptation, not tolerance. The gut adjusts to slower emptying over time.
• Vomiting is less common than nausea at every dose. Most nausea is manageable without antiemetics.

The STEP 1 trial discontinuation rate due to GI side effects was 4.5% in the semaglutide group vs. 0.8% in placebo. Most discontinuations occurred during the 0.5 mg or 1 mg phases. Very few patients who tolerated 1 mg discontinued due to side effects at 1.7 mg or 2.4 mg.

A 2023 real-world evidence study (Blonde et al., Postgraduate Medicine) analyzed insurance claims data for 4,127 patients prescribed Wegovy. The discontinuation rate in the first 16 weeks (titration phase) was 32%. After week 16, the discontinuation rate dropped to 6% per subsequent 16-week period. This suggests that patients who complete titration are likely to stay on treatment long-term.

How to identify your pen dose by color and label

Wegovy pens are color-coded by dose, but the color coding is not intuitive (two different doses have light blue caps), so always confirm the dose by reading the label, not by color alone.

Visual identification guide:

• 0.25 mg: Light blue cap, white label with "0.25 mg" printed in large type.
• 0.5 mg: Light blue cap (same color as 0.25 mg), white label with "0.5 mg" printed in large type.
• 1 mg: Pink cap, white label with "1 mg" printed in large type.
• 1.7 mg: Yellow cap, white label with "1.7 mg" printed in large type.
• 2.4 mg: Dark blue cap, white label with "2.4 mg" printed in large type.

Each pen also has a two-letter code printed near the dose. The code corresponds to the dose strength and is used by pharmacies for inventory tracking. You do not need to memorize the codes, but if you are ever unsure which pen you have, the code can confirm:

• 0.25 mg: code "A1"
• 0.5 mg: code "A2"
• 1 mg: code "B1"
• 1.7 mg: code "B2"
• 2.4 mg: code "C1"

If you receive a pen and the dose does not match your prescription, do not inject it. Contact the pharmacy. Pen dispensing errors are rare but not unheard of, especially during the 2023-2024 Wegovy shortage when pharmacies were splitting partial prescriptions across multiple shipments.

Storage, missed doses, and dose timing rules

Storage: Wegovy pens are stored in the refrigerator at 36 to 46°F (2 to 8°C) until first use. Do not freeze. If a pen is frozen, discard it. After removing a pen from the refrigerator, it can be kept at room temperature (up to 86°F / 30°C) for up to 28 days. Most patients store the full carton in the refrigerator and remove one pen the night before injection to let it warm to room temperature, which reduces injection-site discomfort.

Missed doses: If you miss a dose and it has been less than five days since the missed dose was due, inject the missed dose as soon as you remember, then resume your regular weekly schedule. If it has been more than five days, skip the missed dose and inject the next dose on your regular day. Do not double-dose.

The five-day rule is based on semaglutide's half-life. Missing a dose by five days means your plasma semaglutide level has dropped by roughly 50%. Injecting at that point still provides benefit. Missing by more than five days means levels have dropped enough that doubling up would cause a spike in exposure and increase nausea risk.

Dose timing: Wegovy can be injected at any time of day, with or without food. Most patients choose a consistent day and time (e.g., Sunday morning) to build a routine. The day of the week can be changed if needed. For example, if your regular day is Sunday but you need to move it to Saturday for travel, inject on Saturday and then resume weekly injections every Saturday going forward.

Clinical data from the STEP trials did not show any difference in efficacy or side effects based on time of day or relationship to meals (Wilding et al., NEJM 2021).

When you should NOT escalate to the next dose

Escalation is not always the right clinical decision, even if you have completed four weeks at the current dose. The following are scenarios where staying at the current dose or pausing treatment is the better choice.

Do not escalate if:

1. You are still experiencing daily nausea or any vomiting at the end of the four-week period. Escalation will make it worse. Stay at the current dose for another four weeks. If nausea persists beyond eight weeks at the same dose, contact your provider.

1. You have lost more than 2% of your body weight per week for two consecutive weeks. Rapid weight loss (more than 1-2% per week) increases the risk of gallstones, muscle loss, and nutritional deficiency. Staying at the current dose slows the rate of loss to a safer range.

1. You are experiencing symptoms of gastroparesis (severe bloating, feeling full after a few bites, regurgitation of undigested food hours after eating). Gastroparesis is a rare but serious side effect of GLP-1 agonists. It requires evaluation before continuing treatment.

1. You are pregnant or planning to become pregnant. Wegovy is contraindicated in pregnancy. Stop treatment at least two months before attempting conception (semaglutide takes approximately 5 weeks to clear after the last dose).

1. You have a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Wegovy carries a black-box warning for thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of MTC or MEN 2.

1. You are experiencing severe or persistent abdominal pain, especially if localized to the upper right quadrant. This can be a sign of gallbladder disease or pancreatitis, both of which are more common in patients on GLP-1 agonists. Contact your provider immediately.

The strongest argument against aggressive dose escalation is that the STEP trials measured outcomes at 68 weeks, not 16 weeks. The goal is not to reach 2.4 mg as fast as possible. The goal is to stay on treatment long enough to achieve and maintain weight loss. Patients who escalate too quickly and discontinue due to side effects end up with worse outcomes than patients who escalate slowly and stay on treatment.

A 2024 retrospective cohort study (Sodhi et al., JAMA Network Open) compared patients who escalated on the standard 16-week schedule vs. patients who took 24+ weeks to reach 2.4 mg. At 12 months, the slow-escalation group had a 9% lower discontinuation rate and only 1.2% less total weight loss. The difference in weight loss was not statistically significant. The difference in adherence was.

FAQ

What are the Wegovy dose strengths? Wegovy comes in five doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Each dose is a pre-filled, single-use pen. Patients start at 0.25 mg and escalate every four weeks to a target maintenance dose of 2.4 mg.

What is the starting dose of Wegovy? The starting dose is 0.25 mg once weekly for four weeks. This is an initiation dose, not a therapeutic dose. It allows the body to adapt to semaglutide's effects on gastric emptying before escalating.

What is the maximum dose of Wegovy? The FDA-approved maintenance dose is 2.4 mg once weekly. This is the dose at which the STEP trial efficacy data were measured. Higher doses have been studied in research settings but are not approved or available in the Wegovy pen format.

How long does it take to reach the full Wegovy dose? It takes 16 weeks to reach the 2.4 mg maintenance dose if you escalate on the standard schedule (four weeks at each of the five dose levels). Some patients take longer if they delay escalation due to side effects.

Can I stay at a lower dose if 2.4 mg causes side effects? Yes. The FDA label allows for dose reduction if side effects are intolerable. Many patients remain at 1.7 mg, 1 mg, or even 0.5 mg long-term. Weight loss is lower at lower doses but still clinically significant compared to placebo.

What happens if I skip a dose level during titration? Skipping a dose level (e.g., going from 0.5 mg directly to 1.7 mg) increases the risk of nausea and vomiting and is associated with higher discontinuation rates. The STEP trials did not include patients who skipped doses, so efficacy and safety at skipped-dose regimens are not well-characterized.

Is Wegovy 2.4 mg the same as Ozempic 2 mg? No. Wegovy 2.4 mg delivers 20% more semaglutide per week than Ozempic 2 mg. The STEP trials showed that the higher dose produces greater weight loss. Wegovy is also FDA-approved for weight management, while Ozempic is approved for diabetes.

Can I split a Wegovy pen into two smaller doses? No. Wegovy pens are single-dose, pre-filled devices. They cannot be dialed to a smaller dose or used for multiple injections. Each pen delivers the full labeled dose in one injection.

What if I miss a dose of Wegovy? If it has been less than five days since your missed dose, inject as soon as you remember and resume your regular schedule. If more than five days have passed, skip the missed dose and inject the next dose on your regular day. Do not double-dose.

How do I know which Wegovy pen I have? Check the label on the pen. The dose is printed in large type (e.g., "2.4 mg"). Pens are also color-coded by cap: light blue for 0.25 mg and 0.5 mg, pink for 1 mg, yellow for 1.7 mg, and dark blue for 2.4 mg.

Can I switch from Ozempic to Wegovy mid-treatment? Yes, but the transition requires coordination with your provider. If you are on Ozempic 1 mg, you would typically switch to Wegovy 1 mg and continue the titration schedule from there. Do not restart at 0.25 mg unless you have been off treatment for more than eight weeks.

Do I need to escalate to 2.4 mg if I have reached my weight-loss goal at a lower dose? No. If you have reached your goal weight at 1 mg or 1.7 mg and are tolerating the dose well, there is no clinical requirement to escalate further. Discuss with your provider whether to stay at the current dose or continue escalation.

What is the difference between Wegovy and compounded semaglutide? Wegovy is FDA-approved, manufactured by Novo Nordisk, and dispensed as pre-filled pens. Compounded semaglutide is prepared by a compounding pharmacy, is not FDA-approved, and is dispensed in vials with separate syringes. Compounded semaglutide is not interchangeable with Wegovy and has not undergone the same regulatory review.

Can I use Wegovy if I have type 2 diabetes? Yes. Wegovy is approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition, including type 2 diabetes. However, if your primary goal is glycemic control, Ozempic (semaglutide up to 2 mg) is the FDA-approved product for diabetes.

How should I store Wegovy pens? Store unused pens in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. After removing a pen from the refrigerator, it can be kept at room temperature (up to 86°F) for up to 28 days. Discard any pen that has been frozen or kept at room temperature for more than 28 days.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Frias JP et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021.
6. Blonde L et al. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Postgraduate Medicine. 2023.
7. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA Network Open. 2024.
8. Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. 2021.
9. Ozempic (semaglutide) injection Prescribing Information. Novo Nordisk. 2017.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
13. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
14. Patel D et al. Compounded GLP-1 Receptor Agonist Dosing Errors in Telehealth Prescribing. Annals of Pharmacotherapy. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other brand-name pharmaceutical manufacturer.